Blastic Plasmacytoid Dendritic Cell Neoplasm Pipeline Research Report 2022 Featuring AbbVie, ImmunoGen, Mustang Bio, & Genentech - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blastic Plasmacytoid Dendritic Cell Neoplasm - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

The "Blastic Plasmacytoid Dendritic cell neoplasm - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Blastic Plasmacytoid Dendritic cell neoplasm pipeline landscape.

The assessment part of the report embraces, in depth Blastic Plasmacytoid Dendritic cell neoplasm commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic Plasmacytoid Dendritic cell neoplasm collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Blastic Plasmacytoid Dendritic cell neoplasm R&D. The therapies under development are focused on novel approaches to treat/improve Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blastic Plasmacytoid Dendritic cell neoplasm Emerging Drugs Chapters

This segment of the Blastic Plasmacytoid Dendritic cell neoplasm report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Blastic Plasmacytoid Dendritic cell neoplasm Emerging Drugs

Venetoclax: Genentech

Venetoclax (RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis. This molecule is being developed in collaboration with AbbVie.Currently, the drug is being developed in Phase 1 for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pivekimab sunirine: ImmunoGen

IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). IMGN632 uses one of ImmunoGen's (the "Company") novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.

The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN. In December 2020, the Company announced that it aligned with FDA on a path to full approval for IMGN632, with an amendment to the ongoing 801 Phase 1/2 study to add a new cohort of up to 20 frontline BPDCN patients, with CR/CRc rate as the primary endpoint.

MB 102: Mustang Bio

MB102 (CD123) is over expressed in 75-89% of AML patients and over 90% in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients. There were an estimated 19,520 new U.S. cases of AML in 2018 with an estimated 25% 5-year survival rate. BPDCN is an ultra-rare disease and aggressive blood cancer with 500-1,000 patients per year in the U.S. and a median overall survival of 9-12 months. MB-102 has shown promising response rates in early small populations of these patients in a physician IND study out of City of Hope.

Key Players

• AbbVie
• ImmunoGen
• Mustang Bio
• Genentech

Key Products

• Venetoclax
• Pivekimab sunirine
• MB 102
• Azacitidine

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/d0zzzo